OptiBiotix Health PLC Scientific and commerical update (4390N)
26 October 2016 - 5:00PM
UK Regulatory
TIDMOPTI
RNS Number : 4390N
OptiBiotix Health PLC
26 October 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Scientific and Commercial Update
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces a scientific and commercial update.
Scientific Update
OptiBiotix has made significant progress in its scientific
programmes to develop compounds which modify the human microbiome
to prevent, manage and treat disease. The Company believes these
developments have the potential to substantially increase the
Company's value. These include: -
1. Demonstration in human gut models of the ability of its
microbiome modulators to increase the growth rate of specific
microbial species in the human microbiome. This has now been
demonstrated in multiple species, including OptiBiotix's
cholesterol reducing strain (LP-LDL (TM) )
2. Demonstration in human gut models of the ability of its
microbiome modulators to enhance a biological effect, such as
cholesterol reduction. In the presence of microbiome modulators,
OptiBiotix's cholesterol reducing strain (LP-LDL (TM) ) showed a
threefold increase in cholesterol reduction
OptiBiotix believes that this is the first time that anyone has
demonstrated a targeted change in the microbiome leading to an
enhanced biological activity and improved health benefit
(cholesterol reduction). This creates the opportunity for: -
1. Designer ingredients or supplements which can modify an
individual's current microbiome to improve health
2. Combining microbiome modulators with existing products such
as probiotics, a market that is expected to be worth more than
$46.5bn by 2020 (Markets and Markets)
The results of these studies will be presented at a Microbiome
Summit in November 2016 and in a number of publications in
mainstream scientific journals at the start of 2017.
Commercial Update
The publication of results from our successful human cholesterol
study and scientific studies demonstrating our products mechanism
of action will support the launch of a range of cardiovascular
products to reduce LDL cholesterol, blood pressure, and
cardiovascular risk, anticipated for the spring of 2017. These
studies, once published, provide the scientific evidence for sales
and marketing literature to provide product differentiation and
support higher margins.
OptiBiotix has been building an extensive IP portfolio, a
supporting scientific evidence base, a brand (LP-LDL (TM) ), a
range of product formulations, and a supporting manufacturing,
distribution and sales structure with partners to support a product
launch in spring 2017 and commercialisation of its technology.
Christian Hansens recent acquisition of a single microbial strain
(LGG) from Valio for US$82m demonstrates the potential value the
industry places on a recognised brand (LGG), supporting science and
commercial sales.
Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has
made significant progress in the last six months in developing its
science, building its IP portfolio, and gaining commercial traction
with steadily growing revenues from partnerships and products
sales. OptiBiotix's weight management division is now profitable
with growing sales of GoFigure products and great consumer feedback
and reorders. This announcement provides shareholders with a
scientific and commercial update on its cardiovascular product
range which has been the subject of multiple ongoing discussions
with partners across the supply chain. The aim of these discussions
is to ensure OptiBiotix derives the maximum value for shareholders
across the broad range of interlinked product opportunities which
span both consumer and pharmaceuticals. OptiBiotix believes
building the science and IP, and developing the brand across
multiple products opportunities creates the potential for risk
diversification and high shareholder return."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7148
7900
Liam Murray
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKESAEXKFFF
(END) Dow Jones Newswires
October 26, 2016 02:00 ET (06:00 GMT)